NASDAQ:SPRB Spruce Biosciences (SPRB) Stock Forecast, Price & News $2.36 +0.02 (+0.85%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$2.30▼$2.4150-Day Range$1.92▼$2.6052-Week Range$0.95▼$3.57Volume394,866 shsAverage Volume970,164 shsMarket Capitalization$93.81 millionP/E RatioN/ADividend YieldN/APrice Target$7.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Spruce Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside222.0% Upside$7.60 Price TargetShort InterestHealthy2.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector586th out of 981 stocksPharmaceutical Preparations Industry271st out of 462 stocks 3.5 Analyst's Opinion Consensus RatingSpruce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.60, Spruce Biosciences has a forecasted upside of 222.0% from its current price of $2.36.Amount of Analyst CoverageSpruce Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.89% of the outstanding shares of Spruce Biosciences have been sold short.Short Interest Ratio / Days to CoverSpruce Biosciences has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Spruce Biosciences has recently decreased by 12.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpruce Biosciences does not currently pay a dividend.Dividend GrowthSpruce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRB. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for SPRB on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spruce Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Spruce Biosciences is held by insiders.Percentage Held by Institutions84.21% of the stock of Spruce Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spruce Biosciences are expected to remain at ($1.50) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spruce Biosciences is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spruce Biosciences is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpruce Biosciences has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spruce Biosciences (NASDAQ:SPRB) StockSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.Read More Receive SPRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spruce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRB Stock News HeadlinesMay 25, 2023 | finance.yahoo.comSpruce Biosciences Appoints Percival Barretto-Ko to Board of DirectorsMay 24, 2023 | finance.yahoo.comSpruce Biosciences to Participate in the Jefferies Healthcare ConferenceJune 8, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 23, 2023 | msn.comOppenheimer Reiterates Spruce Biosciences (SPRB) Outperform RecommendationMay 22, 2023 | finance.yahoo.comSpruce Biosciences Honored at CARES Foundation 15th Annual Everyone CARES GalaMay 17, 2023 | msn.comRBC Capital Reiterates Spruce Biosciences (SPRB) Outperform RecommendationMay 16, 2023 | msn.comCredit Suisse Reiterates Spruce Biosciences (SPRB) Outperform RecommendationMay 16, 2023 | msn.comJMP Securities Reiterates Spruce Biosciences (SPRB) Market Outperform RecommendationJune 8, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 16, 2023 | markets.businessinsider.comAnalyst Expectations for Spruce Biosciences's FutureMay 16, 2023 | finance.yahoo.comInvestors in Spruce Biosciences (NASDAQ:SPRB) have seen decent returns of 63% over the past yearMay 16, 2023 | markets.businessinsider.comSpruce Biosciences (SPRB) Gets a Buy from JMP SecuritiesMay 15, 2023 | finance.yahoo.comSpruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesMay 4, 2023 | finance.yahoo.comSpruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual MeetingApril 11, 2023 | americanbankingnews.comCocrystal Pharma (NASDAQ:COCP) versus Spruce Biosciences (NASDAQ:SPRB) Critical SurveyApril 2, 2023 | americanbankingnews.comEquities Analysts Offer Predictions for Spruce Biosciences, Inc.'s Q1 2023 Earnings (NASDAQ:SPRB)April 1, 2023 | americanbankingnews.comSpruce Biosciences, Inc. Forecasted to Post Q4 2023 Earnings of ($0.36) Per Share (NASDAQ:SPRB)March 31, 2023 | finance.yahoo.comSpruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should KnowMarch 24, 2023 | americanbankingnews.comSpruce Biosciences (NASDAQ:SPRB) Price Target Lowered to $10.00 at HC WainwrightMarch 23, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Spruce BiosciencesMarch 22, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Spruce Biosciences, Inc. Raised by Analyst (NASDAQ:SPRB)March 21, 2023 | americanbankingnews.comSpruce Biosciences (NASDAQ:SPRB) Stock Rating Reaffirmed by Credit Suisse GroupMarch 18, 2023 | markets.businessinsider.comSpruce Biosciences (SPRB) Receives a Buy from Credit SuisseMarch 16, 2023 | finance.yahoo.comSpruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate UpdatesMarch 1, 2023 | finance.yahoo.comSpruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 23, 2023 | finance.yahoo.com2 “Strong Buy” Penny Stocks With Multibagger PotentialFebruary 13, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Petiq (PETQ) and Spruce Biosciences (SPRB)See More Headlines SPRB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRB Company Calendar Last Earnings3/16/2023Today6/07/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRB CUSIPN/A CIK1683553 Webwww.sprucebiosciences.com Phone415-655-4168FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.60 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+223.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,180,000.00 Net MarginsN/A Pretax Margin-2,403.72% Return on Equity-54.88% Return on Assets-44.48% Debt Debt-to-Equity Ratio0.03 Current Ratio5.97 Quick Ratio5.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book0.81Miscellaneous Outstanding Shares39,750,000Free Float36,725,000Market Cap$93.41 million OptionableNot Optionable Beta2.28 Key ExecutivesMr. Michael G. Grey (Age 69)Exec. Chairman Comp: $65kMr. Samir M. Gharib CPA (Age 40)CPA, M.B.A., Pres & CFO Comp: $480kDr. Javier Szwarcberg M.D. (Age 52)M.P.H., CEO & Director Dr. Ralph William Charlton III (Age 52)M.D., Chief Medical Officer Dr. Libbie Mansell M.B.A.Ph.D., Chief Regulatory & Quality OfficerMs. P. J. RamtinSr. VP of Bus. OperationsMore ExecutivesKey CompetitorsGalectin TherapeuticsNASDAQ:GALTVaccitechNASDAQ:VACCSpero TherapeuticsNASDAQ:SPROSCYNEXISNASDAQ:SCYXBriaCell TherapeuticsNASDAQ:BCTXView All CompetitorsInstitutional OwnershipJPMorgan Chase & Co.Bought 58,168 shares on 5/18/2023Ownership: 0.146%Armistice Capital LLCBought 3,928,000 shares on 5/16/2023Ownership: 9.883%Alyeska Investment Group L.P.Bought 1,000,000 shares on 5/16/2023Ownership: 2.516%CVI Holdings LLCBought 472,000 shares on 5/16/2023Ownership: 1.188%Two Sigma Advisers LPBought 37,600 shares on 5/15/2023Ownership: 0.095%View All Institutional Transactions SPRB Stock - Frequently Asked Questions Should I buy or sell Spruce Biosciences stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spruce Biosciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRB shares. View SPRB analyst ratings or view top-rated stocks. What is Spruce Biosciences' stock price forecast for 2023? 5 equities research analysts have issued 12 month price targets for Spruce Biosciences' stock. Their SPRB share price forecasts range from $4.00 to $10.00. On average, they expect the company's stock price to reach $7.60 in the next year. This suggests a possible upside of 223.4% from the stock's current price. View analysts price targets for SPRB or view top-rated stocks among Wall Street analysts. How have SPRB shares performed in 2023? Spruce Biosciences' stock was trading at $1.0974 at the start of the year. Since then, SPRB stock has increased by 114.1% and is now trading at $2.35. View the best growth stocks for 2023 here. When is Spruce Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our SPRB earnings forecast. How were Spruce Biosciences' earnings last quarter? Spruce Biosciences, Inc. (NASDAQ:SPRB) posted its earnings results on Thursday, March, 16th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.08. When did Spruce Biosciences IPO? (SPRB) raised $75 million in an initial public offering on Friday, October 9th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets served as the underwriters for the IPO. What is Spruce Biosciences' stock symbol? Spruce Biosciences trades on the NASDAQ under the ticker symbol "SPRB." Who are Spruce Biosciences' major shareholders? Spruce Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.88%), RiverVest Venture Management LLC (7.39%), Carlyle Group Inc. (7.29%), AIGH Capital Management LLC (2.78%), Alyeska Investment Group L.P. (2.52%) and CVI Holdings LLC (1.19%). Insiders that own company stock include Bali Muralidhar, Camilla V Simpson, Holdings A/S Novo and Venture Fund Iii L Rivervest. View institutional ownership trends. How do I buy shares of Spruce Biosciences? Shares of SPRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spruce Biosciences' stock price today? One share of SPRB stock can currently be purchased for approximately $2.35. How much money does Spruce Biosciences make? Spruce Biosciences (NASDAQ:SPRB) has a market capitalization of $93.41 million. The company earns $-46,180,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. How can I contact Spruce Biosciences? The official website for the company is www.sprucebiosciences.com. The company can be reached via phone at 415-655-4168 or via email at investors@sprucebiosciences.com. This page (NASDAQ:SPRB) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.